Paradigm Biopharmaceuticals Ltd (ASX: PAR) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Paradigm Biopharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $413.56 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 229.61 million
Earnings per share -0.126
Dividend per share N/A
Year To Date Return -28.63%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Paradigm Biopharmaceuticals Ltd (ASX: PAR)
Latest News

PAR ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) forthe lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).

PAR Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Sep 2021 $1.82 $-0.11 -5.71% 1,107,613 $1.94 $1.94 $1.82
16 Sep 2021 $1.93 $0.00 0.00% 319,907 $1.91 $1.97 $1.91
15 Sep 2021 $1.93 $0.01 0.52% 324,152 $1.92 $1.94 $1.90
14 Sep 2021 $1.92 $-0.03 -1.54% 250,410 $1.95 $1.97 $1.92
13 Sep 2021 $1.95 $0.02 1.04% 224,548 $1.95 $1.98 $1.94
10 Sep 2021 $1.93 $-0.02 -1.03% 357,775 $1.95 $1.96 $1.91
09 Sep 2021 $1.95 $-0.05 -2.50% 538,591 $1.98 $2.01 $1.93
08 Sep 2021 $2.00 $0.08 4.16% 413,508 $1.93 $2.01 $1.93
07 Sep 2021 $1.93 $-0.02 -1.03% 239,676 $1.95 $1.96 $1.92
06 Sep 2021 $1.95 $-0.10 -4.90% 472,086 $2.02 $2.04 $1.95
03 Sep 2021 $2.04 $0.10 5.14% 1,014,410 $1.95 $2.11 $1.92
02 Sep 2021 $1.95 $0.01 0.52% 130,054 $1.95 $1.98 $1.95
01 Sep 2021 $1.94 $-0.04 -2.02% 411,442 $1.98 $2.01 $1.94
31 Aug 2021 $1.98 $0.00 0.00% 709,432 $1.99 $2.03 $1.95
30 Aug 2021 $1.98 $0.06 3.13% 600,835 $1.95 $2.00 $1.89
27 Aug 2021 $1.92 $-0.05 -2.54% 517,915 $1.96 $1.98 $1.88
26 Aug 2021 $1.97 $-0.02 -1.01% 441,726 $1.99 $2.01 $1.95
25 Aug 2021 $1.99 $0.06 3.11% 342,584 $1.93 $1.99 $1.93
24 Aug 2021 $1.93 $-0.01 -0.52% 373,526 $1.96 $1.97 $1.92
23 Aug 2021 $1.94 $0.01 0.52% 671,037 $1.95 $2.00 $1.91
20 Aug 2021 $1.93 $0.03 1.58% 309,293 $1.93 $1.95 $1.93

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
19 Nov 2020 Christopher Fullerton Transfer 1 $3,050,000
Off-market transfer. Assuming 1,000,000 Indirect shares transferred to Direct shares
19 Nov 2020 Christopher Fullerton Transfer 1 $3,050,000
Off-market transfer. Assuming 1,000,000 Indirect shares transferred to Direct shares
19 Nov 2020 Paul Rennie Buy 600 $1,830,000
As advised by the company. Employee Share Plan
19 Nov 2020 Donna Skerrett Buy 500 $1,525,000
As advised by the company. Employee Share Plan

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Helen E Fisher Non-Executive Director Feb 2021
Ms Fisher has knowledge of the health care sector, combined with her commercial experience and technical background in law, science and finance. Helen is CEO and managing director of Bio Capital Impact Fund (BCIF) and a Non-Executive Director (NED) and Chair of the Audit and Risk Committee of Calix Limited (ASX: CXL), a company with a platform technology with applications in climate change, water management, biotech and pharmaceutical areas. Helen previously held a NED and Chair of the Audit and Risk Committee position at Sienna Cancer Diagnostics Limited before it was acquired by BARD1 (ASX:BD1). Helen is currently the chair of the Victorian branch of AusBiotech. Helen has provided strategic tax advice to publicly listed and multinational companies and has experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP and supply chain management. She will also Chair of the Risk Committee of PAR from 23/02/2021.
Mr Paul Rennie Chief Executive OfficerManaging DirectorInterim Chairman May 2014
Mr Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul's experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their Director of business development. Paul also led the commercialisation of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company.
Mr Amos Meltzer Non-Executive Director Dec 2020
Mr Meltzer has over 25 years of experience in international trade and in commercialising technologies & in the life sciences. He has overseen life science research and product development projects as well as clinical trials and the sale and marketing of a pharmaceutical product. Amos' experience and knowledge is drawn from having worked in both law firms (Freehills and K&L Gates) and in house counsel and IP director at two Nasdaq-listed companies ( Nasdaq:Cgen and, Nasdaq:Gilt), as a non-executive director of a biotechnology company (, Nasdaq:evgn), and as VP of Business Development and then CEO of an ASX-listed biopharmaceutical company (, ASX:IMC). In these roles, he included a disciplines; R&D, product development, clinical operations, business development and investor relations. Amos currently serves Chief Operating Officer of neuro-medical device company Synchron (, chairman of the board of surgeon education services company Vasculab ( and as a legal advisor to a number of ASX listed and private life science companies.
Mr John Gaffney Non-Executive Director Sep 2014
Mr Gaffney have more than 30 years experience. He brings to the board a compliance and corporate governance background and is experienced in financial services compliance. John also has corporate and commercial experience having worked with a major national law firm as a senior lawyer and also practised as a Barrister at the Victorian Bar. Previously John has been a Non-Executive Director of a US based biotechnology company. He is member of Risk Committee.
Dr Donna Skerrett Executive Director Jul 2020
Dr Skerrett has experience from her more than 30 years in the Pharmaceutical Industry. Dr Skerrett has more than three decades of experience in transfusion medicine, cellular therapy and transplantation. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Centre in New York from 2004 to 2011 and served as Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University's New York-Presbyterian Hospital from 1999 to 2004. Dr Skerrett has been an advisor to the New York State Department of Health on the Progenitor Cell Committee since 1989 and a board Member of the Alliance for Regenerative Medicine since 2014. From 2004, she held roles at Mesoblast in clinical and regulatory affairs until she was appointed Chief Medical Officer in 2011. She previously chaired the New York State Council on Blood and Transfusion Services and currently serves on the Board of Directors of the Fox Chase Cancer Centre in Philadelphia and the Board of Visitors of Lewis Katz School of Medicine in Philadelphia. Dr Skerrett joined the Paradigm team in September 2019, where she was appointed Chief Medical Officer with her primary role to manage the company's clinical development programs across Paradigm's entire indication pipeline.
Mr Kevin G Hollingsworth Company Secretary
Kevin G Hollingsworth Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 13,293,732 5.86%
Kzee Pty Ltd <Kzee Superannuation Fund A/C> 10,781,467 4.75%
J P Morgan Nominees Australia Pty Limited 7,966,450 3.51%
Paul John Rennie 7,630,400 3.36%
CS Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> 5,106,723 2.25%
Citicorp Nominees Pty Limited 5,010,176 2.21%
Nancy Edith Wilson-Ghosh <Ghosh Family A/C> 3,860,835 1.70%
MJGD Nominees Pty Ltd <Bsmi A/C> 2,768,232 1.22%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 2,700,323 1.19%
V Redford Pty Ltd <Redford S/F A/C> 2,505,419 1.10%
Mr Evan Philip Clucas + Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 2,427,913 1.07%
Mr Brett Langan 2,403,432 1.06%
JGM Investment Group Pty Ltd <Muchnicki Family A/C> 2,185,715 0.96%
Sandhurst Trustees Ltd <Collins St Value Fund A/C> 2,177,947 0.96%
Himstedt & Co Pty Ltd <The Himstedt Family A/C> 1,921,871 0.85%
BNP Paribas Noms Pty Ltd <Drp> 1,820,100 0.80%
Irwin Biotech Nominees Pty Ltd <Bioa A/C> 1,802,490 0.79%
View 26 Pty Ltd <View 26 A/C> 1,650,000 0.73%
Ms Lenna Yu Ling Tye 1,521,631 0.67%
Australian Executor Trustees Limited <No 1 Account> 1,492,100 0.66%